Ambryon Biosciences

AAV9 Serotype

Breakthrough serotype capable of crossing the blood-brain barrier systemically. Revolutionized CNS gene therapy with broad neuronal and glial transduction. FDA-approved for spinal muscular atrophy.

Characteristics

Crosses blood-brain barrier after systemic administration. Broad CNS transduction (neurons, astrocytes, motor neurons). Efficient cardiac and skeletal muscle transduction. Uses terminal galactose as receptor. Age-dependent BBB penetration (more efficient in neonates). Moderate pre-existing immunity. Foundation for PHP and myoAAV engineering.

Applications

Spinal muscular atrophy (Zolgensma - FDA approved, most expensive drug). Giant axonal neuropathy (clinical trials). Duchenne muscular dystrophy. CLN6 Batten disease. Cardiac gene therapy. Most successful CNS gene therapy vector to date.

Tropism

CNS (neurons, astrocytes), cardiac muscle, liver, skeletal muscle (broad systemic)

Sequence1 bp

Sign in to view the full sequence.

Sign in

References

  1. 1.Mendell et al. (2017). Single-dose gene-replacement therapy for spinal muscular atrophy. N Engl J Med — Mendell 2017 Zolgensma

Identifiers & revision